Yu-Hao Huang1,#, Hao-Yeh Chen2,#, Peng-Ju Chien1, Chun-Yu Chen2,3, Shao-Ti Li4, Hsueh-Te Lee5, Yueh-Chun Lee4,6,*, Wen-Wei Chang1,7,*
Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.080978
- 16 June 2026
Abstract Backgrounds: Triple-negative breast cancer (TNBC) is highly aggressive, insensitive to radiotherapy, and exhibits increased cancer stem cell (CSC) properties, contributing to poor patient outcomes. B-cell lymphoma 2 (BCL2) associated transcription factor 1 (BCLAF1) is an oncogene in certain cancers, but its role in TNBC is unclear. This study investigated BCLAF1’s involvement in radioresistance and CSC activity in TNBC. Methods: BCLAF1 expression and clinical significance were analyzed using The Cancer Genome Atlas (TCGA) breast cancer dataset. Radioresistant MDA-MB-231 cells were used to examine BCLAF1’s function. Proto-oncogene SRC (SRC) overexpression, BCLAF1 knockdown, dasatinib treatment, and hypoxia inducible factor 1 subunit… More >